Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

• Market Cap: ₹122.83B
• Dividend Yield: 0.8%
• Average Volume (3M): 12.81K
• Price to Earnings (P/E): 54.6
• Beta (1Y): 1.08
• Revenue Growth: 3.63%
• EPS Growth: -1.21%
• Country: IN
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.30
• Shares Outstanding: 104,616,200
• 10 Day Avg. Volume: 31,605
• 30 Day Avg. Volume: 12,808
• PEG Ratio: 2.27
• Price to Book (P/B): 9.60
• Price to Sales (P/S): 14.50
• P/FCF Ratio: 127.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 30.08
• Revenue Forecast (FY): ₹12.66B

• Rating: 66 Neutral
• Price Target: ₹1,251.00 ▼(-6.54% Downside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by strong financial performance (healthy profitability and a low-leverage balance sheet). This is offset by weak technicals (below key moving averages and negative MACD) and a relatively high P/E with only a modest dividend yield.

Positive Factors

Low leverage and strong balance sheet

A low debt-to-equity ratio and high equity financing provide durable financial flexibility. This reduces refinancing risk, supports investment in capacity or regulatory compliance, and helps the company weather demand swings without eroding operational capability or jeopardizing manufacturing expansion plans.

Consistent positive operating cash flow

Sustained positive operating cash flow ensures the business can fund working capital, incremental capex and process development internally. That persistent cash generation underpins long-term manufacturing reliability and reduces dependence on external financing for strategic projects or capacity scaling.

Specialized fermentation-based API manufacturing capability

Deep fermentation and downstream-processing expertise is a structural competitive advantage in complex APIs. High technical barriers, regulatory know-how and customer reliance on reliable supply create durable customer relationships, potential pricing power and operating leverage as utilization rises.

Negative Factors

Inconsistent free cash flow growth

Fluctuating free cash flow growth constrains the firm’s ability to commit to large, multi-year investments or return capital consistently. Variability increases the likelihood of periodic external financing for strategic projects and reduces predictability of funding for capacity expansion or new product scale-up.

Slight gross margin pressure

A declining gross margin, even if modest, suggests rising input or manufacturing costs or pricing pressure. Over several quarters this can erode operating profitability and limit the payoff from revenue growth, forcing management to invest in efficiency gains or accept lower long-term margins.

Customer/product concentration risks

Reliance on a concentrated set of products or large customers makes revenue and utilization vulnerable to order variability or contract loss. For an API manufacturer, losing a key customer or facing demand shifts on a few molecules can materially reduce plant utilization and earnings for extended periods.

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

How the Company Makes Money

Concord Biotech primarily makes money by manufacturing and selling APIs to pharmaceutical companies in domestic and international markets. Its key revenue stream is API sales, where it earns revenue based on contracted/PO-based supply of fermentation-based molecules (notably immunosuppressants and certain oncology-related products), with pricing and volumes driven by customer demand, product mix, and regulatory approvals/market access in end markets. A secondary revenue stream comes from finished-dosage/formulation business conducted through licensing/marketing and distribution arrangements with other pharmaceutical companies (where Concord supplies product and partners commercialize, or Concord supplies intermediates/APIs used in partner products); specific partner terms and the split between API and formulations revenue are null. Additional contributors to earnings typically include process development and scale-up services tied to its manufacturing capabilities and the benefit of operating leverage from high utilization of its fermentation and purification infrastructure; precise contribution amounts are null. Major factors influencing profitability include capacity utilization of fermentation facilities, yields and cost efficiencies in complex manufacturing, regulatory compliance enabling exports, and customer concentration/product concentration dynamics; quantified exposures are null.

Concord Biotech Ltd. Financial Statement Overview

Summary

Strong overall fundamentals: solid revenue and profitability trends (Income Statement 85) and a very robust, low-leverage balance sheet (Balance Sheet 88). Cash generation is positive (Cash Flow 78), but inconsistent free cash flow growth and slight gross margin pressure temper the score.

Income Statement

Concord Biotech Ltd. has demonstrated strong revenue growth over the years, with a notable increase from 2020 to 2025. Gross profit margin and net profit margin are robust, reflecting efficient cost management and operational success. The EBIT and EBITDA margins indicate solid profitability, with consistent growth. However, the gross profit margin has slightly decreased, signaling potential cost pressures that need monitoring.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio, indicating minimal financial leverage and risk. The equity ratio is high, showing significant equity financing. Return on equity is commendable, highlighting effective use of shareholder funds. Overall, the company shows financial stability and prudent financial management.

Cash Flow

Operating cash flow is consistently positive and growing, underscoring effective cash management. Free cash flow also shows positive trends, although growth has fluctuated across the years. The operating cash flow to net income ratio is favorable, indicating good cash conversion from profits. However, the free cash flow growth rate has been inconsistent, presenting potential challenges in sustaining capital investments.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.25B	12.00B	10.17B	8.53B	7.13B	6.17B
Gross Profit	7.51B	7.68B	6.67B	6.61B	5.41B	5.00B
EBITDA	4.56B	5.13B	4.39B	3.53B	2.78B	3.29B
Net Income	3.23B	3.72B	3.08B	2.40B	1.75B	2.35B
Balance Sheet
Total Assets	20.23B	20.34B	17.01B	15.14B	13.13B	11.83B
Cash, Cash Equivalents and Short-Term Investments	3.81B	3.18B	2.86B	1.81B	1.62B	2.01B
Total Debt	16.07M	29.69M	97.38M	315.47M	624.93M	892.83M
Total Liabilities	1.96B	2.22B	1.74B	2.24B	2.10B	1.83B
Stockholders Equity	18.27B	18.13B	15.27B	12.90B	11.03B	9.99B
Cash Flow
Free Cash Flow	975.85M	1.36B	1.80B	1.01B	519.70M	-373.59M
Operating Cash Flow	1.51B	2.47B	2.65B	2.46B	2.07B	1.67B
Investing Cash Flow	-212.84M	-1.63B	-1.55B	-1.58B	-1.12B	-1.95B
Financing Cash Flow	-1.13B	-986.67M	-992.15M	-852.19M	-1.00B	311.24M

Concord Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1338.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1338.6 is above the 20-day moving average (MA) of 1177.41, above the 50-day MA of 1238.83, and below the 200-day MA of 1536.12, indicating a bearish trend. The MACD of -12.49 indicates Negative momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 39.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CONCORDBIO	66 Neutral	₹122.83B	54.58	―	0.80%	3.63%	-1.21%
BLUEJET	65 Neutral	₹65.47B	57.24	―	0.22%	63.34%	109.89%
BIOCON	63 Neutral	₹635.91B	91.56	―	0.12%	10.62%	-66.88%
JUBLINGREA	61 Neutral	₹92.05B	59.25	―	0.74%	3.80%	64.94%
SYNGENE	61 Neutral	₹162.83B	439.86	―	0.19%	8.57%	-2.93%
PPLPHARMA	55 Neutral	₹193.14B	-41.77	―	0.08%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Concord Biotech Ltd. Corporate Events

Concord Biotech Updates Key Managerial Authorisations for Market Disclosures

Concord Biotech Limited has revised the list of key managerial personnel (KMPs) authorized to determine the materiality of events and information and to make corresponding disclosures to stock exchanges under SEBI’s Listing Obligations and Disclosure Requirements. The updated authorized KMPs now include Chairman and Managing Director Sudhir Vaid, Joint Managing Director and CEO Ankur Vaid, Chief Financial Officer Raviraj Karia, and Company Secretary and Compliance Officer Hina Patel, a move that formalizes the company’s internal governance framework for market disclosures and reinforces its compliance processes for timely and accurate communication with investors and regulators.